This study evaluated the outcome of endovascular and conservative treatment for giant cavernous carotid artery aneurysms (CCAAs). We retrospectively reviewed a series of 35 consecutive giant CCAAs treated with endovascular and conservative treatment. All patients were evaluated by balloon occlusion test (BOT) before treatment. Patients who could tolerate BOT were treated by parent artery occlusion (PAO), those who could not tolerate BOT were treated by stent/coil or conservative methods.
Introduction
Giant CCAAs are most often located outside the subarachnoid space. The mass effect attendant on CCAAs may produce compression of the adjacent third to sixth cranial nerves and result in symptoms such as headache, facial pain or ophthalmoplegia/paresis. Rupture may lead to symptomatic or asymptomatic direct cavernous-carotid fistula or severe intractable epistaxis. Subarachnoid hemorrhage can occur when the lesion erodes through the dura or dural rings of the carotid artery 1, 2 . Direct surgical obliteration of giant CCAAs has been possible but remains a formidable challenge. The intimate relationship between the intracavernous carotid artery and venous structures and the cranial nerves make surgical access difficult. Persistent morbidity with surgical therapy and steady advances in endovascular therapy have encouraged attempts at endovascular repair of giant CCAAs. Treatment strategy includes parent artery occlusion (PAO) and selective coiling with or without stent assistance. However, few large series have examined endovascular body weight/min). After the mean arterial pressure was reduced to two thirds of baseline, hypotension was maintained for 20 minutes provided that the mean arterial blood pressure not less than 55 mmHg. If the patient tolerated BOT under hypotension, he/she was considered clinically able to tolerate parent vessel occlusion. The test was terminated immediately if any neurologic deficit developed during test occlusion under normotensive or hypotensive conditions.
Patients who could tolerate BOT were treated by PAO, those who could not tolerate BOT were treated by stent/coil or conservative methods, and the asymptomatic patient was treated by conservative methods.
Periprocedure Medications
When the use of a stent was planned, patients were premedicated with antiplatelet therapy consisting of aspirin 100 mg and clopidogrel 75 mg for three days before the procedure. After the procedure, clopidogrel (75 mg/ day) was recommended for an additional 30 days, and aspirin (100 mg/day) was recommended for six months. After PAO, patients were treated with hypervolemia.
Results and Outcome Evaluation
The degree of the aneurysm occlusion was classified as: complete obliteration (dense coil packing with no contrast filling the aneurysm); neck remnant (contrast filling a very small "dog ear" portion at one side of the neck or or conservative treatment of giant CCAAs. The goal of the present study was to investigate the risk factors and outcome of giant CCAAs treated by endovascular and conservative management.
Material and Methods
Thirty-five consecutive patients with 35 giant CCAAs were enrolled between January 2006 and September 2011 in our center. There were 29 women (82.9%) and six men (17.1%), with a mean age of 52.4 years (range, 18-78 years). Twenty-six patients presented with cranial neuropathies, eight patients presented with headache, and one patient was asymptomatic (detected incidentally during neuroradiological imaging because of an unrelated medical condition). The median aneurysm size was 29.6 mm, ranging from 25 to 45 mm. All patients were evaluated by balloon occlusion test (BOT) before treatment as reported by previous authors [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
Tolerance to test occlusion was assessed by a detailed neurologic examination consisting of evaluation of cranial nerve function, muscle strength, and language ability every five minutes or when a deficit was perceived. The test occlusion was considered positive if any new neurologic deficit occurred, that is clinically intolerant patients. If the patient tolerated 20 minutes of normal tension, the balloon was deflated for ten minutes, and then the test was repeated under hypotension after another 20 minutes. Hypotension was induced by the infusion of sodium nitroprusside (2.5 to 7.5 mg/kg 
Clinical Follow-up
Of the eight conservatively treated giant CCAAs, symptoms were worsened in four patients (50%) (more than six years after symptom onset), three remained unchanged (less than three years after symptom onset), improved in one at 33.6±19.9 months (6~65 months) follow-up. Of the 27 endovascularly treated giant CCAAs, at 33.1±17.4 months (4~71months) follow-up examination symptoms were resolved in 13 (48.1%), improved in nine (33.3%), worsened in two (7.4%), and unchanged in three (11.1%), a good clinical outcome (mRS 0-1) was observed in 25 (92.6%) patients. Procedure-related morbidity and mortality was 7.4 % and 0, respectively.
Statistical Analysis
Patient sex, presentation, and size (<35 mm vs ≥35 mm) did not significantly correlate with worsening symptoms, risk factors for poor clinical outcome included age of 60 years and older (P=0.006), and conservative treatments (P= 0.038). There was no significant difference in the final outcome, whether the parent vessels were occluded or preserved (P=0.698).
Discussion
Most CCAAs are considered benign lesions, and have a natural history with a low risk of life-threatening complications. The management of CCAAs has been controversial 3-7 . Diaz et al. 8 treated 32 symptomatic CCAAs. Nine received progressive ligation of the internal carotid artery in the neck with a Selverstone clamp and a surface superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis, two (22.2%) developed transient neurological deficits. Seven underwent trapping of the internal carotid artery and a deep STA-MCA anastomosis. Two patients (28.6%) developed a cerebral infarction, one of whom died; 15 had direct clipping of the aneurysm. Two patients (13.3%) progressed from marked visual loss to blindness of the same side, and one (6.7%) developed an intraventricular hemorrhage during induction of anesthesia and died without surgery. within interstices between the coils at the level of the neck only); incomplete occlusion (coil packing is usually less dense). The length of the angiographic follow-up period was 11.7±15.2 months (range, 3-63 months). The clinical follow-up was classified by Modified Rankin Scale (mRS) scores at the last clinic visit or by telephone call.
Statistical Analysis
Logistic regression was performed to evaluate the association between sex, age (younger than 60 years vs 60 years and older), presentation, size (<35 mm vs ≥35 mm), treatment type (endovascular vs conservative treatment) and worsening outcome. The significance level was set at 0.05.
Results

Initial Results
Six patients failed BOT and refused endovascular or surgical treatment, one patient was asymptomatic, and one patient refused endovascular or surgical treatment because of old age (73 years old) ( Table 1) . Twenty-seven aneurysms were treated with endovascular methods. Seventeen aneurysms were treated by PAO (eight with coils, five with balloons, two with balloon and coils, two with coils and onyx), eight aneurysms were treated with stent-assisted coil embolization (one Neuroform, one Leo, six Enterprise), and two aneurysms were simply coiled ( Table 2) .
Of the 27 endovascularly treated giant CCAAs, the initial post-procedure angiograms revealed complete occlusion, neck remnant, and incomplete occlusion in 22 (81.5%), three (11.1%), and two (7.4%), respectively ( Figures  1 and 2 ). Periprocedural infarcts occurred in two patients (7.4%), one caused by thromboembolic strokes after stent/coil and one as a result of hemodynamic insufficiency after PAO. 19 had residual aneurysm in 50% of endovascularly treated aneurysms >1 cm. Malisch et al. 20 found a 33% recanalization rate in giant aneurysms that were part of their study in 1997. The overall rate of aneurysm recanalization after coil embolization may be significantly higher in giant and very large aneurysms compared with smaller lesions [21] [22] [23] . Regrowth of the aneurysm, coil compaction, and coil migration into soft intra-aneurysmal thrombus are possible explanations for the faster recanalization 20 .
Parent Artery Occlusion
Parent artery occlusion (PAO) is a therapeutic modality for patients who can tolerate BOT [9] [10] [11] [12] . Complications of PAO include early or late stroke and 'de novo' aneurysm formation at a distant site because of hemodynamic changes in the circle of Willis [13] [14] [15] [16] . There remains a 5% to 10% risk of serious stroke with associated morbidity/mortality after PAO despite tolerated BOT 17 . In our patient group, of the 17 aneurysms treated by PAO, one (5.9%) developed postocclusion ischemic infarction. No new aneurysms were found in our patients. However, longer term follow-up data will be needed to draw definitive conclusions regarding new aneurysm formation.
Stent-Assisted Coiling
The disadvantage of stent/coil therapy is the frequently incomplete occlusion of the aneurysm with the need for multiple treatments low-up. Patients with asymptomatic giant CCAAs who cannot tolerate carotid artery occlusion should be treated with caution. Vasconcellos et al. 26 reported five cases of giant CCAAs which evolved with spontaneous thrombosis of the internal carotid artery, and four patients had regression of deficit. They believe that spontaneous thrombosis of the internal carotid artery is a common outcome in giant CCAAs, and is related to a significant improvement of symptoms. In our series, spontaneous thrombosis of the internal carotid artery occurred in one patient, and symptoms were cured. We think thrombosis of the internal carotid artery evolved from a dissecting cavernous carotid artery aneurysm. This may be catastrophic for those patients without efficient collateral circulation.
Effect of Endovascular Treatment
Mass effect symptoms will probably improve with the shrinkage of aneurysms after embolization. Shrinkage of approximately 57% of ini-
Conservative Treatment
Lye and Jha 24 reported ten CCAAs managed conservatively (mean 6.9 years). Three (30%) improved, six (60%) were unchanged and one (10%) died following intracranial hemorrhage. Linskey et al. 3 observed 20 CCAAs without treatment (5 months ~13 years, median 2.4 years): symptoms were worsened in seven (35%), unchanged in nine (45%), and improved in four (20%). Goldenberg et al. 5 reported ten CCAAs without intervention, three (30%) remained stable, and seven (70%) worsened. In our study, the outcome of conservatively treated giant CCAAs was negative: four (50%) worsened, three (37.5%) were unchanged and one (12.5%) improved. Choulakian et al. 25 concluded that consideration should be given to the treatment of asymptomatic CCAAs 15 mm or larger due to the potential risks of cranial neuropathy and SAH. In our series, an asymptomatic giant aneurysm (the largest dimension 25 mm) was still unchanged after 31 months fol- treated patients are not comparable because their selection was biased according to severity of symptoms. The sizes of their cavernous carotid artery aneurysms were not mentioned. Smaller CCAAs may be followed conservatively, and our study shows that giant symptomatic CCAAs should be treated.
Recently, flow diverters, such as the Pipeline embolization device (ev3, Irvine, CA, USA) and the Silk stent (Balt Extrusion, Montmorency, France), offer a novel therapeutic alternative for many of these same lesions [31] [32] [33] [34] . Although initial published results indicate a generally favorable risk-benefit profile for flow diverters, early and delayed complications, such as ipsilateral intraparenchymal hemorrhage and in-stent thrombosis, are increasingly reported [35] [36] [37] [38] . While these results provide a shortterm benchmark versus flow diverters, the long-term comparison remains unstudied and these data do little to address the debate.
Conclusion
Risk factors for poor clinical outcome of giant CCAAs included conservative treatment and age older than 60 years. A symptomatic giant cavernous carotid aneurysm should be treated. The outcome of endovascular treatment of giant CCAAs is promising. tial volume after 18 months of endosaccular coiling has been reported 27 . Gruber et al. 28 reported that 45.5% of patients with symptoms of neural compression improved after endosaccular embolization of giant and very large aneurysms. Niiro et al. 13 analyzed the results of the long-term follow-up of 11 patients with a giant or large cavernous sinus aneurysm treated by only proximal occlusion between 1975 and 1989. Eight of the 11 patients (72.7%) showed improvement of cranial nerves paresis or headache. Hassan et al. 29 observed 28 giant aneurysms treated by PAO with or without intra-aneurysmal occlusion: symptoms were resolved in 19 (68%), improved in four (14%), and unchanged in five (18%). In our series, symptoms were resolved or improved in 81.4%. Steibel-Kalish et al. 7 retrospectively reviewed 185 patients with 206 CCAAs. Seventy-four CCAAs underwent treatment, and 115 patients were followed for four years. They revealed that the treated group had a higher proportion of neurological and visual complications than those who were not treated. This result is different from ours. The reason probably was that 67 cases in the treated group were treated by PAO. Most of them were treated with balloons, and only five were treated with coils. The incidence of complications caused by coils in aneurysm treatment is lower than that caused by balloons 30 . Their two groups of treated and un-
